AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26739331 — intervention group
Group type: COMPARATOR
Intervention: Control group learning using solely a box trainer with standard laparoscopic view.
Number of subjects: 54
Study 26739331 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups receive a standardized introduction to the training center, laparoscopic instruments, and C‐loop technique.
Number of subjects: 54
Study 25299806 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Network for Improvement of Addiction Treatment (NIATx) change team approach
Number of subjects: 0
Study 25299806 — intervention group
Group type: COMPARATOR
Intervention: Usual approach to implement improved HIV services
Number of subjects: 0
Study 22341703 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication review by a pharmacist
Number of subjects: 323
Study 22341703 — intervention group
Group type: COMPARATOR
Intervention: Usual health care (Control)
Number of subjects: 323
Study 19811776 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg d‐cycloserine
Number of subjects: 31
Study 19811776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 18030641 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead poisoning preventive education
Number of subjects: 95
Study 15642799 — intervention group
Group type: EXPERIMENTAL
Intervention: pioglitazone (30 mg/day)
Number of subjects: 34
Study 15642799 — intervention group
Group type: EXPERIMENTAL
Intervention: metformin (850 mg, three times a day)
Number of subjects: 34
Study 11289292 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic Scalpel
Number of subjects: 34
Study 9723669 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% loteprednol etabonate
Number of subjects: 133
Study 9723669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 8039988 — intervention group
Group type: EXPERIMENTAL
Intervention: Ear-based temperature measurements using infrared thermometers
Number of subjects: 30
Study 8039988 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal temperature measurements
Number of subjects: 30
Study 8039988 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary temperature measurements
Number of subjects: 30
Study 2656908 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone followed by alpha-interferon
Number of subjects: 41
Study 2656908 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon treatment
Number of subjects: 41
Study 2656908 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 41
Study 31327652 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB and MenC-CRM
Number of subjects: 0
Study 31327652 — intervention group
Group type: COMPARATOR
Intervention: MenC-CRM
Number of subjects: 0
Study 29141376 — intervention group
Group type: EXPERIMENTAL
Intervention: AGI grade I
Number of subjects: 80
Study 29141376 — intervention group
Group type: EXPERIMENTAL
Intervention: AGI grade II
Number of subjects: 80
Study 29141376 — intervention group
Group type: EXPERIMENTAL
Intervention: AGI grade III
Number of subjects: 80
Study 29141376 — intervention group
Group type: EXPERIMENTAL
Intervention: AGI grade IV
Number of subjects: 80
Study 25961614 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid
Number of subjects: 60
Study 25961614 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 60
Study 25961614 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP levels
Number of subjects: 60
Study 25961614 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP test
Number of subjects: 60
Study 23090093 — intervention group
Group type: EXPERIMENTAL
Intervention: Limaprost
Number of subjects: 61
Study 23090093 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 61
Study 23090093 — intervention group
Group type: EXPERIMENTAL
Intervention: Limaprost plus NSAIDs
Number of subjects: 61
Study 23090093 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (Limaprost + NSAIDs)
Number of subjects: 61
Study 22158670 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (vitamin C 120 mg, vitamin E 30 mg, beta-carotene 6 mg, selenium 100 μg, zinc 20 mg)
Number of subjects: 8112
Study 22158670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8112
Study 19496400 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching adhesive system with acid etching and no attrition, no loading
Number of subjects: 8
Study 19496400 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching adhesive system with no attrition, with loading
Number of subjects: 8
Study 19496400 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching adhesive system with attrition
Number of subjects: 8
Study 19496400 — intervention group
Group type: COMPARATOR
Intervention: Self-etching adhesive system without attrition and acid-etching but with loading
Number of subjects: 8
Study 19496400 — intervention group
Group type: COMPARATOR
Intervention: Self-etching adhesive system without attrition and loading but with acid etching
Number of subjects: 8
Study 16689037 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric rehabilitation weight loss program (12 weeks)
Number of subjects: 36
Study 16689037 — intervention group
Group type: COMPARATOR
Intervention: Matched control group
Number of subjects: 36
Study 15120937 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation (ABMT)
Number of subjects: 0
Study 15120937 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 11168307 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared photosensors (PPG method)
Number of subjects: 181
Study 11168307 — intervention group
Group type: COMPARATOR
Intervention: Continuous wave Doppler (Doppler method)
Number of subjects: 181
Study 10220218 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory-training program involving computer-assisted teaching of imagery-based mnemonic strategies for recall of lengthy lists of words and for associating names with faces
Number of subjects: 8
Study 10220218 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory-training program
Number of subjects: 8
Study 10220218 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory training of those with MS
Number of subjects: 8
Study 7824599 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% sucrose solution
Number of subjects: 40
Study 7824599 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy age‐matched female controls)
Number of subjects: 40
Study 7824599 — intervention group
Group type: COMPARATOR
Intervention: Patients with a history of anorexia nervosa
Number of subjects: 40
Study 2969799 — intervention group
Group type: EXPERIMENTAL
Intervention: urapidil (120 mg/day initially, increased to 180 mg/day if necessary)
Number of subjects: 29
Study 2969799 — intervention group
Group type: COMPARATOR
Intervention: methyldopa (100 mg/day initially, increased to 1500 mg/day if necessary)
Number of subjects: 29
Study 29241077 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guided combined pectoral nerve blocks (PECS I and II) with general anesthesia
Number of subjects: 60
Study 29241077 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia only
Number of subjects: 60
Study 28733812 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 63
Study 28733812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 26299216 — intervention group
Group type: EXPERIMENTAL
Intervention: O‐SES (Orsiro)
Number of subjects: 2530
Study 26299216 — intervention group
Group type: COMPARATOR
Intervention: N‐BES (Nobori)
Number of subjects: 2530
Study 23787720 — intervention group
Group type: COMPARATOR
Intervention: Placebo arm of the EVEREST trial
Number of subjects: 1850
Study 21382484 — intervention group
Group type: EXPERIMENTAL
Intervention: MMRV vaccine with a 4-week interval between doses (MMRV-4W)
Number of subjects: 559
Study 21382484 — intervention group
Group type: EXPERIMENTAL
Intervention: MMRV vaccine with a 12-month interval between doses (MMRV-12M)
Number of subjects: 559
Study 21382484 — intervention group
Group type: COMPARATOR
Intervention: MMR vaccine with a 4-week interval between doses (MMR)
Number of subjects: 559
Study 19035430 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and surgical reconstruction
Number of subjects: 121
Study 19035430 — intervention group
Group type: COMPARATOR
Intervention: Training only
Number of subjects: 121
Study 16722837 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonselective NSAIDs
Number of subjects: 205
Study 16722837 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin users
Number of subjects: 205
Study 16722837 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 205
Study 16722837 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidiabetic medication
Number of subjects: 205
Study 12057040 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1200 mg/m2 over 30 minutes on days 1 and 8 every 21 days plus trastuzumab 4 mg/kg over 90 minutes, followed by 2 mg/kg weekly.
Number of subjects: 38
Study 12057040 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine/trastuzumab treatment
Number of subjects: 38
Study 10460066 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg l-menthol capsule
Number of subjects: 12
Study 10460066 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg menthol in mint candy or mint tea
Number of subjects: 12
Study 10460066 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 12
Study 7796526 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft contact lenses
Number of subjects: 85
Study 1971650 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g CAZ administered 140 min prior to puncture (group I)
Number of subjects: 25
Study 1971650 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x 2 g CAZ one day before and 2 g 2 h prior to puncture (group II)
Number of subjects: 25
Study 1971650 — intervention group
Group type: EXPERIMENTAL
Intervention: CAZ concentrations at 4 h after infusion
Number of subjects: 25
Study 1971650 — intervention group
Group type: EXPERIMENTAL
Intervention: CAZ concentrations at 6 h after infusion
Number of subjects: 25
Study 383133 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG in weekly scarifications for 3 years
Number of subjects: 43
Study 383133 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (Control)
Number of subjects: 43
Study 6639290 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation group
Number of subjects: 59
Study 6639290 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help support group
Number of subjects: 59
Study 6639290 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 59
Study 6639290 — intervention group
Group type: COMPARATOR
Intervention: Low-risk group (controls)
Number of subjects: 59
Study 30005584 — intervention group
Group type: EXPERIMENTAL
Intervention: DBT skills training adjunctive to individual treatment as usual (TAU)
Number of subjects: 31
Study 30005584 — intervention group
Group type: COMPARATOR
Intervention: Individual treatment as usual (TAU) only
Number of subjects: 31
Study 27029784 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral distraction
Number of subjects: 82
Study 27029784 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive avoidance
Number of subjects: 82
Study 27437887 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad5.hAC6 (3.2 × 10^9 to 10^12 virus particles)
Number of subjects: 56
Study 27437887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 27437887 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad5.hAC6 (D4 + 5 doses)
Number of subjects: 56
Study 27437887 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad5.hAC6
Number of subjects: 56
Study 24640801 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.06 mg/kg 1 minute before succinylcholine
Number of subjects: 90
Study 24640801 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.06 mg/kg 5 minutes before succinylcholine
Number of subjects: 90
Study 24640801 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 5 ml as placebo 1 minute before succinylcholine
Number of subjects: 90
Study 22732780 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g fosfomycin trometamol
Number of subjects: 60
Study 22732780 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antibiotic)
Number of subjects: 60
Study 20964826 — intervention group
Group type: EXPERIMENTAL
Intervention: 125I-transperineal prostatic brachytherapy (TPPB) with adjuvant androgen deprivation therapy (ADT)
Number of subjects: 420
Study 20964826 — intervention group
Group type: COMPARATOR
Intervention: 125I-transperineal prostatic brachytherapy (TPPB) without adjuvant androgen deprivation therapy (ADT)
Number of subjects: 420
Study 20964826 — intervention group
Group type: EXPERIMENTAL
Intervention: 125I-transperineal prostatic brachytherapy (TPPB) with adjuvant ADT
Number of subjects: 420
Study 20964826 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy results at 36 months following treatment
Number of subjects: 420
Study 16855015 — intervention group
Group type: EXPERIMENTAL
Intervention: Education with husbands
Number of subjects: 442
Study 16855015 — intervention group
Group type: COMPARATOR
Intervention: Education alone
Number of subjects: 442
Study 16855015 — intervention group
Group type: COMPARATOR
Intervention: No education
Number of subjects: 442
Study 16284985 — intervention group
Group type: COMPARATOR
Intervention: Four courses of standard-dose consolidation therapy without maintenance (Arm A)
Number of subjects: 789
Study 16284985 — intervention group
Group type: EXPERIMENTAL
Intervention: Three courses of standard-dose consolidation with six courses of maintenance therapy (Arm B)
Number of subjects: 789
Study 12170044 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine microcapsules with dexamethasone
Number of subjects: 12
Study 12170044 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine microcapsules without dexamethasone
Number of subjects: 12
Study 10462658 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic variceal sclerotherapy alone
Number of subjects: 69
Study 10462658 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic variceal band ligation plus low-dose endoscopic variceal sclerotherapy
Number of subjects: 69
Study 8578731 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Blood Filtration (WBF)
Number of subjects: 40
Study 8578731 — intervention group
Group type: COMPARATOR
Intervention: Conventional Filtration (CF)
Number of subjects: 40
Study 1967516 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg vecuronium
Number of subjects: 40
Study 1967516 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg vecuronium
Number of subjects: 40
Study 1967516 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg vecuronium
Number of subjects: 40
Study 1967516 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg vecuronium
Number of subjects: 40
Study 347467 — intervention group
Group type: COMPARATOR
Intervention: 20 mg prodipin infusion (group 1)
Number of subjects: 28
Study 347467 — intervention group
Group type: COMPARATOR
Intervention: Continued therapy without prodipin (group 2)
Number of subjects: 28
Study 347467 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg prodipin infusion (group 3)
Number of subjects: 28
Study 31676120 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-Flux Electrolyzed Acidic Solution (CFEAS)
Number of subjects: 19
Study 31676120 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (control)
Number of subjects: 19
Study 30196720 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR‐PACE program
Number of subjects: 126
Study 30196720 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 126
Study 28417897 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral magnesium supplementation (800 mg magnesium oxide daily)
Number of subjects: 102
Study 28417897 — intervention group
Group type: COMPARATOR
Intervention: Control group (no magnesium supplementation)
Number of subjects: 102
Study 26552185 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoraleae Fructus (40 g x kg(‐1))
Number of subjects: 35
Study 26552185 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoraleae Fructus and Glycyrrhizae Radix et Rhizoma (40 + 20 g x kg(‐1))
Number of subjects: 35
Study 26552185 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control group (distilled water)
Number of subjects: 35
Study 26552185 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive control (aristolochic acid A) group
Number of subjects: 35
Study 26552185 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycyrrhizae Radix et Rhizoma group
Number of subjects: 35
Study 23406914 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive mechanical ventilation (NIV)
Number of subjects: 200
Study 23406914 — intervention group
Group type: COMPARATOR
Intervention: Oxygen therapy
Number of subjects: 200
Study 21485075 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical plum-blossom needle
Number of subjects: 60
Study 21485075 — intervention group
Group type: COMPARATOR
Intervention: Physical comprehensive therapy
Number of subjects: 60
Study 18722583 — intervention group
Group type: COMPARATOR
Intervention: D1 surgery
Number of subjects: 3432
Study 18722583 — intervention group
Group type: COMPARATOR
Intervention: D2 surgery
Number of subjects: 3432
Study 18722583 — intervention group
Group type: COMPARATOR
Intervention: D3 surgery
Number of subjects: 3432
Study 17547588 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine (5-15 mg/day)
Number of subjects: 46
Study 17547588 — intervention group
Group type: COMPARATOR
Intervention: Topiramate (25-600 mg/day)
Number of subjects: 46
Study 17547588 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 46
Study 17547588 — intervention group
Group type: COMPARATOR
Intervention: Topiramate
Number of subjects: 46
Study 15503549 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical gel treatment for severe periodontitis
Number of subjects: 31
Study 12086119 — intervention group
Group type: EXPERIMENTAL
Intervention: New site-specific measure of quality of life for breast problems
Number of subjects: 1063
Study 12086119 — intervention group
Group type: COMPARATOR
Intervention: Generic quality of life scale (SF-36)
Number of subjects: 1063
Study 9468466 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized treatment with adjusted doses of methotrexate, teniposide, and cytarabine based on drug clearance rates.
Number of subjects: 182
Study 9468466 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy with fixed doses of methotrexate, teniposide, and cytarabine based on body-surface area.
Number of subjects: 182
Study 9468466 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized treatment for B-lineage leukemia patients.
Number of subjects: 182
Study 9468466 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy for T-lineage leukemia patients.
Number of subjects: 182
Study 9468466 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate in individualized treatment.
Number of subjects: 182
Study 8542807 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (5-ASA) 2.4 g daily by mouth
Number of subjects: 60
Study 8542807 — intervention group
Group type: COMPARATOR
Intervention: Control (not treated)
Number of subjects: 60
Study 8542807 — intervention group
Group type: COMPARATOR
Intervention: Both groups (5-ASA and Control)
Number of subjects: 60
Study 2193998 — intervention group
Group type: EXPERIMENTAL
Intervention: imipenem/cilastatin
Number of subjects: 27
Study 2193998 — intervention group
Group type: COMPARATOR
Intervention: standard broad spectrum antibiotic therapy
Number of subjects: 27
Study 438787 — intervention group
Group type: EXPERIMENTAL
Intervention: LT (long term, unlimited length of stay, mean 179 days)
Number of subjects: 173
Study 438787 — intervention group
Group type: COMPARATOR
Intervention: ST (short term, 90‐day limit)
Number of subjects: 173
Study 31697336 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous dosing (4g/24h after a loading dose of 1g)
Number of subjects: 59
Study 31697336 — intervention group
Group type: COMPARATOR
Intervention: Intermittent dosing (1g every 6h)
Number of subjects: 59
Study 31260707 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer influence
Number of subjects: 0
Study 31260707 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert influence
Number of subjects: 0
Study 31260707 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert influence for consumers low in insect-based disgust sensitivity
Number of subjects: 0
Study 29972287 — intervention group
Group type: EXPERIMENTAL
Intervention: Community mobilization (CM) intervention
Number of subjects: 1156
Study 29972287 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 1156
Study 26983031 — intervention group
Group type: EXPERIMENTAL
Intervention: ALF-5755
Number of subjects: 57
Study 26983031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 24834865 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel IUD
Number of subjects: 42
Study 24834865 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper T380A IUD
Number of subjects: 42
Study 24834865 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 42
Study 22182261 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 126
Study 22182261 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 126
Study 22182261 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Processing Therapy (CPT) and Prolonged Exposure (PE)
Number of subjects: 126
Study 19156894 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive timing (phase 1)
Number of subjects: 0
Study 19156894 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (phase 2)
Number of subjects: 0
Study 19156894 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy, autologous SCT, and allogeneic SCT (phase 2)
Number of subjects: 0
Study 17484870 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (12.5 mg/kg/dose every 6 hours for 14 days)
Number of subjects: 182
Study 17484870 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 182
Study 15110741 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 20